FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* CHEN JIN-LONG (Last) (First) (Middle) 333 OYSTER POINT BOULEVARD (Street) SOUTH SAN FRANCISCO CA 94080					2. Issuer Name and Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC NGM] 3. Date of Earliest Transaction (Month/Day/Year) 10/31/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)									eck all applicable) X Director 10% O X Officer (give title below) Chief Scientific Officer Individual or Joint/Group Filing (Check Apple) X Form filed by One Reporting Person				over specify specify specify specify specify specificable
(S	•																	
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date,		3.		4. Securities Acquired (A) or			5. Amou Securiti Benefici Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(11341.4)
Common Stock 10			10/31	/2019				M		28,376	A	\$1.4	\$1.44		3,319		D	
Common Stock 10/3		10/31	/2019)19					28,376	D	\$12.98	886 ⁽²⁾	924	1,943		D		
Common Stock 11/		11/01	/2019)19					11,403	A	\$1.4	1.44 936		,346		D		
Common Stock		11/01/2019)		S ⁽³⁾		11,403	D	\$13.28	881(4)	924	4,943		D			
Common Stock		11/01	11/01/2019				M ⁽⁵⁾		71,750	A	\$0.5	0.52		6,693		D		
Common Stock 1		11/04	4/2019				M		10,986	A	\$1.4	1,00		7,679		D		
Common Stock 11		11/04	/2019				S ⁽⁶⁾		10,986	D	\$12.26	.2605 ⁽⁷⁾		6,693		D		
		Table I												wned				
Derivative Conversion Date Ex Security or Exercise (Month/Day/Year) if a		Execution if any	emed 4. ion Date, Transa Code (5. Number of		6. Date Exerc		cisable and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		nt 8.	erivative ecurity	derivative Securities Beneficial Owned Following Reported	e S Illy	Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Numbe	r					
\$1.44	10/31/2019			M			28,376	(8)		03/01/2022	Common Stock	150,5	00	\$1.44	4 122,12		D	
\$1.44	11/01/2019			М			11,403	(8)		03/01/2022	Common Stock	122,1	24	\$1.44	110,72	!1	D	
\$0.52	11/01/2019			М			71,750	(8)		02/24/2020	Common Stock	143,5	00	\$0.52	71,75	0	D	
\$1.44	11/04/2019			М			10,986	(8)		03/01/2022	Common Stock	110,7	21	\$1.44	99,73	5	D	
	SAN C. (SECURITY (Instance) SECURITY (Instance) Stock	SAN CA (State) Tal Security (Instr. 3) Stock S	SAN CA 94080 SECO CA	SAN SCO CA 94080 SECURITY SECURITY STATE SECURITY SECURITY	Note	STER POINT BOULEVARD	STER POINT BOULEVARD 3. Date of Earl 10/31/2019 4. If Amendment 5. Table II - Derivative 5. Stock 11/01/2019 5. Stock 11/01/2019 5. Stock 11/04/2019 5.	SAN CA 94080 Security (Instr. 3) 2. Transaction Date Month/Day/Year) Stock 11/01/2019 Stock 11/04/2019 Stock	STER POINT BOULEVARD	STOCK	SAN CA 94080 Security (Instr. 3) 2, Transaction Month/Day/Year) 2, Transaction Month/Day/Year) Month/D	SAN SCO CA 94080 Security (Instr. 3) 2. Transaction Month/Day/Year) Month/Day/Year)	STER POINT BOULEVARD SAN CA 94080 SCO COO COO	Stock	NGM BIOPHARMACEUTICALS INC Comment Convention	Content Cont	NGM B OPHARMACEUTICALS INC Chocked all applicability Chief Scientific Chocked all applicability Chief Scientific Ch	Common C

- 1. The reporting person sold 28,376 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on November 1, 2019.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$12.70 to \$13.32. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The reporting person sold 11,403 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on November 1, 2019.
- 4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$13.00 to \$13.52. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- 5. Pursuant to its terms, the option to purchase these shares expires on February 24, 2020, unless earlier exercised. This transaction represents the exercise of a portion of this incentive stock option by the reporting
- 6. The reporting person sold 10,986 shares of common stock in anticipation of a potential alternative minimum tax liability resulting from his exercise of a portion of an incentive stock option covering 71,750 shares of common stock on November 1, 2019.
- 7. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$12.04 to \$12.76. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

 $8. \ All \ shares \ underlying this option have vested.$

Remarks:

/s/ Jin-Long Chen

11/04/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.